Why the New Science of Psychedelic-Assisted Therapy Is Moving Faster Than Any Regulatory Framework Can Handle

The majority of the nation hasn’t fully embraced the strange development that is taking place in American psychiatry. President Trump signed an executive order on a Saturday afternoon in mid-April instructing federal agencies to expedite research on psilocybin, MDMA, and ibogaine—drugs that, until recently, were only mentioned in passing by medical professionals at conferences. The order has a blatant political bias in favor of veterans’ mental health and $50 million in federal funding. However, the fact that this is occurring is not surprising to anyone who has been monitoring the clinical trial data for the last ten years. It’s the speed at which it’s coming.

For years, the science has been slowly advancing, yielding findings that seriously challenge the conventional psychiatric paradigm. Psilocybin-assisted psychotherapy has been shown in randomized trials to significantly reduce treatment-resistant depression after just a few sessions. Although the FDA rejected the first large development program due to issues with trial design and blinding, MDMA-assisted therapy has been successful in treating PTSD, especially in combat veterans. That rejection ought to have served as a warning. Rather, the momentum was hardly slowed.

When you enter a PAT clinical trial site, which is located outside of Portland and in Baltimore, you’ll notice how little it resembles a regular psychiatry appointment. The lighting in the room is soft. A blanket, a couch, and a carefully chosen playlist are all present. For six to eight hours, two therapists sit close by. In reality, the “drug” is not the therapy. It’s an experience. That’s the regulatory knot that no one has been able to untie.

The FDA was designed to assess drugs, not drugs plus therapists plus eyewear plus three-day integration sessions. In 2024, the agency did not actually reject MDMA when it rejected Lykos Therapeutics’ MDMA program. Classifying something that doesn’t fit the model was difficult. When participants can clearly tell if they have taken a psychedelic, how can a trial be blinded? How can the presence of a therapist be standardized? The field lacks clear answers, and these are not insignificant questions.

Another more subdued concern, which is primarily expressed in implementation-science circles, is who will actually have access after approval. Participants in clinical trials have typically been well-educated, white, and wealthy. There is virtually no infrastructure to provide an eight-hour therapy session overseen by two qualified clinicians in Federally Qualified Health Centers and VA systems, which serve the populations that are arguably most in need. For years, Dr. Danielle Adams and associates have written about this, mapping the gap using frameworks such as RE-AIM. They have a simple concern: a treatment that is limited to Beverly Hills and Boulder boutique clinics isn’t truly a breakthrough in mental health. It’s a product for wellness.

In the meantime, the political narrative has taken an odd turn. Due in part to the veteran lobby’s unusually strong support, psychedelic reform has emerged as one of the few truly bipartisan issues in Washington. Recently, the Board of Medicine’s Dr. Dave Rabin characterized the change as a shift from treating symptoms to addressing underlying causes. That’s a significant assertion. It might prove to be accurate. It might also be similar to what was said in 1990 regarding SSRIs.

Observing all of this gives the impression that the research community and the regulatory system are operating at different speeds and are unwilling to slow down. There will have to be a compromise. Either the FDA manages to conduct an honest evaluation of combined drug-therapy interventions, or the gap between what is known by science and what patients are legally able to obtain widens. Neither result feels totally at ease. Both seem more and more inevitable.